Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorARLEGUI, Hugo
dc.contributor.authorNACHBAUR, G.
dc.contributor.authorPRAET, N.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEGAUD, Bernard
dc.date.accessioned2021-01-13T10:20:51Z
dc.date.available2021-01-13T10:20:51Z
dc.date.issued2020
dc.identifier.issn2328-8957 (Print) 2328-8957en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/23781
dc.description.abstractEnBackground Although rotavirus vaccines have proven to prevent the risk of rotavirus gastroenteritis (RVGE) in children under 5 years old, they are also associated with an increased transient risk of intussusception (IS). Several quantitative benefit-risk models (qBRm) are performed to measure this balance in hospitalizations and deaths prevented versus the ones induced. Method In this study, our objective was to provide a complete overview of qBRm used for rotavirus vaccination. We systematically searched 3 medical literature databases to identify relevant articles, in English, that were published between 2006 and 2019. Results Of the 276 publications screened, 14 studies using qBRm for rotavirus vaccination were retained, based on preselected criteria. Four were performed in low- and middle-income countries. Almost all (13 of 14) displayed the following characteristics: force of infection assumed to be constant over time (static model), indirect effect of rotavirus vaccination (herd effect) not considered, closed model (individuals not allowed to enter and/or exit the model over time), and aggregated level (no tracking of individual’s behavior). Most of the models were probabilistic (9 of 14) and reported sensitivity and/or scenario analyses (12 of 14). Input parameter values varied across studies. Selected studies suggest that, depending on the models used, for every IS hospitalization and death induced, vaccination would prevent, respectively, 190–1624 and 71–743 RVGE-related hospitalizations and deaths. Conclusions The benefits of rotavirus vaccination were shown to largely exceed the increased risk of IS, across all studies. Future research aiming to harmonize qBRm for rotavirus vaccination should ensure the comparability of studies and provide additional information for regulatory authorities, physicians, and patients.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectPharmacoEpi-Drugs
dc.title.enQuantitative Benefit-Risk Models Used for Rotavirus Vaccination: A Systematic Review
dc.title.alternativeOpen Forum Infect Disen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/ofid/ofaa087en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed32296726en_US
bordeaux.journalOpen Forum Infectious Diseasesen_US
bordeaux.pageofaa087en_US
bordeaux.volume7en_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.issue4en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03167404
hal.version1
hal.date.transferred2021-03-12T08:28:08Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Open%20Forum%20Infectious%20Diseases&rft.date=2020&rft.volume=7&rft.issue=4&rft.spage=ofaa087&rft.epage=ofaa087&rft.eissn=2328-8957%20(Print)%202328-8957&rft.issn=2328-8957%20(Print)%202328-8957&rft.au=ARLEGUI,%20Hugo&NACHBAUR,%20G.&PRAET,%20N.&BEGAUD,%20Bernard&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée